Primary biliary cirrhosis: therapeutic advances.
Publication/Presentation Date
5-1-2013
Abstract
Primary biliary cirrhosis (PBC) is a chronic and slowly progressive cholestatic liver disease characterized by destruction of the interlobular bile ducts, which, if untreated, leads to fibrosis, biliary cirrhosis, and liver failure. Because liver transplantation remains the only curative option for PBC, the goals of treatment are to slow the rate of progression, to alleviate related symptoms, and to prevent complications. Ursodeoxycholic acid is the only US Food and Drug Administration-approved medical treatment of PBC. Several agents are undergoing evaluation as monotherapy or as an adjuvant to ursodeoxycholic acid. This review summarizes current therapeutic advances in the care of patients with PBC.
Volume
17
Issue
2
First Page
229
Last Page
242
ISSN
1557-8224
Published In/Presented At
Czul, F., Peyton, A., & Levy, C. (2013). Primary biliary cirrhosis: therapeutic advances. Clinics in liver disease, 17(2), 229–242. https://doi.org/10.1016/j.cld.2012.12.003
Disciplines
Medicine and Health Sciences
PubMedID
23540499
Department(s)
Department of Medicine
Document Type
Article